AMENDMENTS TO THE SPECIFICATION

Please insert into the published international application the sequence listing attached hereto.

In the specification at page 1, after the title and before line 3, please insert the following:

RELATED APPLICATIONS

This application is a national stage application (under 35 U.S.C. 371) of PCT/EP2004/010911 filed September 30, 2004 which claims benefit to European application 03022311.9 filed October 2, 2003.

In the specification at page 5, line 31, please replace the paragraph entitled "(Preparatory step 1) Single-stranded pEGFP preparation" and starts with "For each PCR", with the following amended paragraph:

For each PCR, 5 U Pfu Turbo polymerase (Stratagene, Amsterdam, Netherlands), 0.2 mM dNTP mix (New England Biolab, Frankfurt, Germany), 12.6 pmol reverse primer (5'-GACCGGCGCTCAGTTGGAATTCTAG-3', SEQ ID NO: 1) and 48.6-54.3 ng plasmid pEGFP (Miniprep, Qiagen, Hilden, Germany) were used. After PCR (95°C for 30 sec 1 cycle, 95°C for 30 sec/55°C for 1 min/68°C for 4 min 40 cycles), 40 U of *Dpn* I was added followed by incubation at 37°C for 3 hours. Product recovery was done using a NucleoSpin Extract (Macherey-Nagel, Düren, Germany; elution volume of 35 µl for 200 µl PCR product).

In the specification at page 6, line 10, please replace the paragraph entitled "(Step 1) PCR with dATPaS" and starts with "For each PCR", with the following amended paragraph:

For each PCR (94°C for 3 min 1 cycle, 94°C for 1 min/59.5°C for 1 min/72°C for 75 sec 31 cycles, 72°C for 10 min 1 cycle), 2.5 U *Taq* DNA polymerase (Qiagen), 0.2 mM dNTP mix (New England Biolab), 0.2 mM Sp-dATPαS (Biolog Life Science Institute, Bremen, Germany), 12.6 pmol 5'-biotinylated forward primer (5'-GACCATGATTACGCCAAGCTTGC-3', SEQ ID

NO: 2), 12.6 pmol reverse primer (5'-GAC CGGCGCTCAGTTGGAATTCTAG-3', SEQ ID NO: 1) and 242.9-271.4 ng plasmid pEGFP (Miniprep; Qiagen) were used.

In the specification at page 7, line 18, please replace the paragraph entitled "(Step 6) Full-length gene synthesis" and starts with "For each PCR", with the following amended paragraph:

For each PCR (94°C for 3 min 1 cycle, 94°C for 1 min/59.5°C + 0.2°C (0.2°C increment for each cycle) for 1 min/72°C for 3 min 30 cycles, 72°C for 10 min 1 cycle), 2.5 U Taq DNA polymerase (Qiagen), 0.2 mM dNTP mix (New England Biolab), 13.3 µl elongated DNA fragment, 20 pmol reverse primer (5'-GAC CGGCGCTCAGTTGGAATTCTAG-3', SEQ ID NO: 1) and 0.66-0.76 µg single-stranded reverse template (preparatory step 1) were used. After synthesizing the full-length gene a purification step was performed using the NucleoSpin Extract (Macherey-Nagel; elution volume of 35 µl for 150 µl PCR product).

In the specification at page 7, line 27, please replace the paragraph entitled "(Step 7) Universal base replacement" and starts with "For each PCR", with the following amended paragraph:

For each PCR (94°C for 3 min 1 cycle, 94°C for 1 min/52.7°C for 1 min/72°C for 75 sec 30 cycles, 72°C for 10 min 1 cycle), 2.5 U Taq DNA polymerase (Qiagen), 0.2 mM dNTP mix (New England Biolabs), 20 pmol forward primer (5'-GACCATGATTACGCCAAGCTTGC-3', SEQ ID NO: 2), 20 pmol reverse primer (5'-GAC CGGCGCTCAGTTGGAATTCTAG-3', SEQ ID NO: 1) and 2.5 µl full-length gene (step 6) were used. The PCR product was purified using NucleoSpin Extract (Macherey-Nagel; elution volume of 50 µl for 150 µl PCR product).